Dihydropyrimidine dehydrogenase deficiency

From Wikipedia, the free encyclopedia

You have new messages (last change).

Dihydropyrimidine dehydrogenase deficiency (DPD deficiency) is a condition in which there is absent or significantly decreased activity of dihydropyrimidine dehydrogenase. Individuals with this condition may develop life-threatening toxicity following exposure to 5-fluorouracil (5-FU), a chemotherapy drug that is used in the treatment of cancer.

Current research suggests that nearly 8% of the population has at least partial DPD deficiency. A diagnostics determination test for DPD deficiency is available and it is expected that with a potential 500,000 people in North America using 5-FU this form of testing will increase.

[edit] References

  • van Kuilenburg A (2006). "Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question.". Cancer Invest 24 (2): 215-7. PMID 16537192.
  • Lee A, Ezzeldin H, Fourie J, Diasio R (2004). "Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-Fluorouracil therapy.". Clin Adv Hematol Oncol 2 (8): 527-32. PMID 16163233.

[edit] External links

This medical article is a stub. You can help Wikipedia by expanding it.
Retrieved from "http://en.wikipedia.org../../../d/i/h/Dihydropyrimidine_dehydrogenase_deficiency.html"